Prognosis and Therapies in Non-Clear Cell Renal Cell Carcinomas.
- 1Department of Hematology & Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72002, USA.
- 2Department of Hematology & Oncology, Renown Health, Reno, NV 89502, USA.
Abstract
Background/objectives
Non-clear cell renal cell carcinoma (nccRCC) comprises biologically heterogeneous renal malignancies with distinct molecular drivers, clinical behavior, and therapeutic responses. This review summarizes prognosis and systemic therapy and evaluates emerging histology-specific and biomarker-directed approaches.Methods
We analyzed overall survival by histology in the SEER 17 Registries database (2000-2022) and conducted a narrative review of trials, guidelines, and translational studies. The ICD-O-3-defined population included 43,966 adults; 43,789 with known survival time were included in survival analyses.Results
Median follow-up was 96 months. Compared with papillary RCC, adjusted HRs were 0.67 (95% CI 0.64-0.70) for chromophobe RCC, 3.73 (3.37-4.11) for collecting duct carcinoma, 0.97 (0.80-1.17) for oncocytic tumors, and 33.23 (27.47-40.20) for medullary carcinoma. VEGFR- and MET-directed therapies and immune checkpoint inhibitor combinations show activity that varies by histology.Conclusions
nccRCC should be studied and managed as a collection of distinct entities. Registry associations require cautious interpretation because of residual confounding, evolving classification, and non-proportional hazards; subtype-specific trials and molecular stratification remain priorities.
Related
- Endothelial p16 expression identifies a subgroup of clear cell renal cell carcinoma with favorable prognosis
- Multi-omics profiling highlights RPLP0 as a potential biomarker for prognosis and response to immunotherapy in clear cell renal cell carcinoma
- VGLL4 Suppresses Malignant Phenotypes of Clear Cell Renal Cell Carcinoma Cells Through Modulation of Hippo/YAP and Wnt/β-Catenin Signaling Pathways
- Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma : A case report
- Pan-cancer analysis identifies ANGPT4 as a potential prognostic biomarker associated with the tumor microenvironment in kidney renal clear cell carcinoma
BibTeX
@article{shrivastava2026prognosis,
title = {{Prognosis and Therapies in Non-Clear Cell Renal Cell Carcinomas.}},
author = {Trilok Shrivastava and Yusra Medik and Nikhila Sampath Kumar and Shi-Ming Tu and Anuradha Kunthur},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18193224},
url = {https://europepmc.org/article/MED/42882918},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prognosis and Therapies in Non-Clear Cell Renal Cell Carcinomas.
AU - Trilok Shrivastava
AU - Yusra Medik
AU - Nikhila Sampath Kumar
AU - Shi-Ming Tu
AU - Anuradha Kunthur
PY - 2026
DA - 2026/10/07
JO - Cancers
DO - 10.3390/cancers18193224
UR - https://europepmc.org/article/MED/42882918
AB - Background/objectives Non-clear cell renal cell carcinoma (nccRCC) comprises biologically heterogeneous renal malignancies with distinct molecular drivers, clinical behavior, and therapeutic responses. This review summarizes prognosis and systemic therapy and evaluates emerging histology-specific and biomarker-directed approaches.Methods We analyzed overall survival by histology in the SEER 17 Registries database (2000-2022) and conducted a narrative review of trials, guidelines, and translational studies. The ICD-O-3-defined population included 43,966 adults; 43,789 with known survival time were included in survival analyses.Results Median follow-up was 96 months. Compared with papillary RCC, adjusted HRs were 0.67 (95% CI 0.64-0.70) for chromophobe RCC, 3.73 (3.37-4.11) for collecting duct carcinoma, 0.97 (0.80-1.17) for oncocytic tumors, and 33.23 (27.47-40.20) for medullary carcinoma. VEGFR- and MET-directed therapies and immune checkpoint inhibitor combinations show activity that varies by histology.Conclusions nccRCC should be studied and managed as a collection of distinct entities. Registry associations require cautious interpretation because of residual confounding, evolving classification, and non-proportional hazards; subtype-specific trials and molecular stratification remain priorities.
SN - 2072-6694
ER -